amitriptyline + estriol

Mi-Gel is a proprietary topical organogel formulation containing a combination of amitriptyline (0.5%) and estriol (0.03%). Developed by Zenith Technology Corporation Limited, it is indicated for the treatment of localized vulvo-vaginal pain conditions, including vulvodynia, pudendal neuralgia, vestibulitis, and dyspareunia. The amitriptyline component acts as a membrane stabilizer by blocking neuronal sodium channels, which reduces mucosal sensitivity and alleviates chronic pain. The estriol component, a weak estrogen, promotes mucosal regeneration, improves tissue flexibility, and enhances lubrication. The drug is currently being evaluated in pivotal bioequivalence trials to support its clinical use as a localized therapy with minimal systemic exposure.

Brand names

Mi-Gel

Other names

amitriptyline 0.5% / estriol 0.03% topical gel